Fund shareholders of BIOXCEL THERAPEUTICS INC
ISIN US09075P2048 · United States · LEI 549300Y25FYZ0E8LW260
- Fund shareholders
- 7
- Of which ETFs
- 0 7 other funds
- Value held
- ≈ 1M $ 707.1K $ · 267.4K €
- Share of capital
- 1.5 % of 31.3M shares on Aug 11, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 207,339 | 277.8K $ | 0.00 % | 0.66 % | as of Mar 31, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 105,533 | 176.2K $ | 0.00 % | 0.34 % | as of Feb 28, 2026 ↗ |
| Select Biotechnology Portfolio Fidelity Select Portfolios | 90,300 | 150.8K $ | 0.00 % | 0.29 % | as of Feb 28, 2026 ↗ |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 34,237 | 57.2K $ | 0.11 % | as of Feb 28, 2026 ↗ | |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 26,610 | 44.4K $ | 0.09 % | as of Feb 28, 2026 ↗ | |
| Total Stock Market Index Trust John Hancock Variable Insurance Trust | 437 | 585.6 $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ABANTE QUANT VALUE, F.I. ABANTE ASESORES GESTION, SGIIC, S.A. | 267.4K € | 1.43 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table counts shares; this one measures what the company weighs inside each fund.
| Fund | Weight in fund | |
|---|---|---|
| ABANTE QUANT VALUE, F.I. ABANTE ASESORES GESTION, SGIIC, S.A. | 1.43 % | as of Dec 31, 2025 ↗ |
| Select Biotechnology Portfolio Fidelity Select Portfolios | 0.00 % | as of Feb 28, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of Feb 28, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 0.00 % | as of Mar 31, 2026 ↗ |
| Total Stock Market Index Trust John Hancock Variable Insurance Trust | 0.00 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each SEC quarterly data set, newest first. The change is read against the quarter before it.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 6 | 0 | 464,456 | +14.9 % |
| 2026Q1 | 6 | 0 | 404,122 | +11.1 % |
| 2025Q4 | 6 | +2 | 363,715 | +740.7 % |
| 2025Q3 | 4 | -2 | 43,263 | +6.2 % |
| 2025Q2 | 6 | 40,728 |
Institutional managers
36 managers declare this company to the SEC (Form 13F); the 25 largest follow.
| Manager | Shares | Value | |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | 1,936,760 | 2.6M $ | as of Mar 31, 2026 |
| ARMISTICE CAPITAL, LLC | 1,910,076 | 2.6M $ | as of Mar 31, 2026 |
| OAKTREE CAPITAL MANAGEMENT LP | 241,188 | 323.2K $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 230,168 | 308.7K $ | as of Mar 31, 2026 |
| JONES FINANCIAL COMPANIES LLLP | 131,789 | 166.1K $ | as of Mar 31, 2026 |
| Man Group plc | 96,473 | 129.3K $ | as of Mar 31, 2026 |
| STATE STREET CORP | 92,118 | 123.4K $ | as of Mar 31, 2026 |
| FMR LLC | 90,300 | 121K $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 84,282 | 112.9K $ | as of Mar 31, 2026 |
| &PARTNERS | 80,864 | 108.4K $ | as of Mar 31, 2026 |
| UBS Group AG | 52,788 | 70.7K $ | as of Mar 31, 2026 |
| Oaktree Fund Advisors, LLC | 42,913 | 57.5K $ | as of Mar 31, 2026 |
| HighTower Advisors, LLC | 41,000 | 54.9K $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 36,313 | 48.7K $ | as of Mar 31, 2026 |
| Beacon Pointe Advisors, LLC | 18,877 | 25.3K $ | as of Mar 31, 2026 |
| OSAIC HOLDINGS, INC. | 16,214 | 21.7K $ | as of Mar 31, 2026 |
| DIVERSIFY WEALTH MANAGEMENT, LLC | 15,000 | 15.6K $ | as of Mar 31, 2026 |
| Portfolio Strategies, Inc. | 12,178 | 16.3K $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 10,588 | 14.2K $ | as of Mar 31, 2026 |
| WELLS FARGO & COMPANY/MN | 4,319 | 5.8K $ | as of Mar 31, 2026 |
| Tower Research Capital LLC (TRC) | 1,718 | 2.3K $ | as of Mar 31, 2026 |
| Silver Grove Financial Group, Inc. | 334 | 447 $ | as of Mar 31, 2026 |
| Washington Trust Advisors, Inc. | 160 | 214 $ | as of Mar 31, 2026 |
| Annis Gardner Whiting Capital Advisors, LLC | 156 | 210 $ | as of Mar 31, 2026 |
| Parkside Financial Bank & Trust | 112 | 151 $ | as of Mar 31, 2026 |
Declared shareholders of BIOXCEL THERAPEUTICS INC
1 beneficial ownership filing. These stakes do not add up: an asset manager filing aggregates its own funds, already counted above.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Armistice Capital, LLC and 1 other | 7.05 % | 1,910,076 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of BIOXCEL THERAPEUTICS INC". https://titelia.com/en/stocks/bioxcel-therapeutics-inc-US09075P2048